about
Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2.Optimization of a type III secretion system-based Pseudomonas aeruginosa live vector for antigen delivery.High-yield production of secreted active proteins by the Pseudomonas aeruginosa type III secretion systemGla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.Questioning the use of an age-adjusted D-dimer threshold to exclude venous thromboembolism: analysis of individual patient data from two diagnostic studies: comment.Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma.Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM).Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations: comment.Antithrombin-independent effects of heparins on fibrin clot nanostructure.Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation.Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French familiesNormal PAI-2 level in French FXII-HAE patientsAdapting a conventional PCR assay for Toxoplasma gondii detection to real-time quantitative PCR including a competitive internal controlLetter by Marlu et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteersEx vivo reversal of the anticoagulant effects of edoxaban - comments on the study by Halim et alLong-term therapy with bevacizumab in a patient with Glanzmann's thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesionsCorrigendum to "Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation" [Thromb. Res. 166 (2018) 113-121]Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently neededReducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive ModelsFibrinography: A Multiwavelength Light-Scattering Assay of Fibrin StructureSplenic infarction associated with transient anti-prothrombin antibodies is a rare manifestation of acute Mycoplasma pneumoniae infectionMulticentre evaluation of CK Prest® for assaying plasma levels of factor IX fused with albumin (Idelvion® )
P50
Q34558230-C0B05C98-EE41-4AED-823E-1BE1D7DF434EQ36452365-28E6FD2C-AB19-4C47-8AD8-C8CA6BE844F0Q39022956-23598386-4A67-42EE-AAA8-EC5AF21E6CC1Q42257925-20E9666F-54FD-44F5-9531-40548689E1F8Q44480758-63A3DE3E-39CB-4324-9C85-8C4C16417EE7Q45872816-D3CD0D4F-A71F-417A-A12E-F18994E78CC0Q48239737-B781E224-5C73-4464-8ABD-83730801FE75Q49823066-D95AB986-FCB1-4B71-9842-00E2261D857EQ53656559-2AD3F5C3-1691-4099-A46B-5EC90DCC518AQ53684581-906A319C-2047-476B-BEA0-79257AE7E1DEQ56977495-EB0E68CB-A455-4415-BFBA-92E48B031521Q56977612-0CBCAD64-B0F2-4DC6-8707-3CFC1A9A2C4BQ80653165-966D518A-DF46-4491-88B4-279D84E8A22BQ83976737-1D5888FB-FCB0-4365-8DC1-24F5C3887252Q84213242-ABD4D8EB-965C-487A-A1ED-67F30F61B955Q86612692-300E350B-1525-4273-ACF4-F9C6FB4E1CF0Q86649108-0172498E-75A0-447A-9661-D199C847A433Q89055620-C0C84E92-680B-4D1E-8F3B-CCE7178EB1C3Q89061997-DDA3E1B8-3099-4690-9253-BFAC05FA5871Q89419650-A6382835-9D2B-4F86-8A1B-926B29041E3EQ91274147-58934D87-E49F-4032-B06A-EAC3B25006B6Q91328214-89819EB3-E6D5-4A5A-A9BF-58D2D7D486EBQ91793576-2A66940B-A1DB-4AC6-ACD7-5761A3C7D489
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raphaël Marlu
@ast
Raphaël Marlu
@en
Raphaël Marlu
@es
Raphaël Marlu
@nl
Raphaël Marlu
@sl
type
label
Raphaël Marlu
@ast
Raphaël Marlu
@en
Raphaël Marlu
@es
Raphaël Marlu
@nl
Raphaël Marlu
@sl
prefLabel
Raphaël Marlu
@ast
Raphaël Marlu
@en
Raphaël Marlu
@es
Raphaël Marlu
@nl
Raphaël Marlu
@sl
P1053
M-7680-2014
P106
P21
P31
P3829
P496
0000-0002-3462-2006